This individualised service supports technologies and teams that need early visibility on market access, HTA, and reimbursement requirements across European countries. The service typically runs over 4–6 weeks and helps innovators understand how future HTA and reimbursement outcomes may affect development priorities, pricing assumptions, and commercial potential. Activities include cross-country assessment of HTA and reimbursement scenarios, review of payer and evidence expectations, identification of access-related evidence gaps, development of price and reimbursement assumptions, and expert input from selected local market access and HTA advisors. Where relevant, the service also supports optimisation of the evidence-generation strategy by integrating likely HTA requirements into development planning. The goal is to reduce downstream reimbursement risk and improve the alignment between product development and future access requirements. Expected outcomes include an early HTA and reimbursement risk map, country-level access assumptions, recommendations to strengthen reimbursement preparedness and price scenarios.